NCT06397872A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

Phase 1

MGL-3196

Healthy

Phase 1

Clinical Trials (1)

NCT04671056Drug Interaction Study of MGL-3196 With Pioglitazone

Phase 1

MGL-3196

Hepatic Impairment

Phase 1

Clinical Trials (1)

NCT04643795Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

Phase 1

Atorvastatin

Healthy

Phase 1

Clinical Trials (1)

NCT02749578Drug Interaction Study of MGL-3196 With Atorvastatin

Phase 1

Resmetirom

MASH - Metabolic Dysfunction-Associated Steatohepatitis

Phase 2

Clinical Trials (1)

NCT07335601Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

Phase 2

MGL-3196

Heterozygous Familial Hypercholesterolemia

Phase 2

Clinical Trials (1)

NCT03038022Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Phase 2

MGL-3196

Non-alcoholic Steatohepatitis

Phase 2

Clinical Trials (1)

NCT02912260Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Phase 2

Placebo

Non-Alcoholic Fatty Liver Disease

Phase 3

Clinical Trials (1)

NCT04197479A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients

Phase 3

Resmetirom

Non-Alcoholic Fatty Liver Disease

Phase 3

Clinical Trials (1)

NCT04951219A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Phase 3

MGL-3196

NASH - Nonalcoholic Steatohepatitis

Phase 3

Clinical Trials (1)

NCT03900429A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

Phase 3

Resmetirom

NASH

Phase 3

Clinical Trials (1)

NCT05500222A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

Phase 3

Open Jobs (56)

Madrigal Pharmaceuticals(MDGL)

Products & Portfolio (1)

Pipeline & Clinical Trials

Open Jobs (56)

Director, Medical Writing

Senior Manager, Regulatory Operations Systems Veeva RIM Product Owner

Director, Patient Experience and Access Marketing

Director, Global Publications Lead

Senior Director, Thought Leader Liaisons Northeast

Senior Administrative Assistant

Associate Director, Transparency Reporting

Manager, Ad Promo & Labeling

Senior Director, Regulatory Strategy

International Congress Lead

Associate Director, Regulatory Operations Global Submission Management

Director, Clinical Pharmacology

Director Finance France/Italy/Spain

Principal Talent Access Partner (Contract)

Benefits Manager (Contract)

Senior Director, US Commercial Strategy & Operations Planning

Executive Director, Strategic Projects

Director, Clinical Operations

Director, Trade Accounts

Senior Clinical Trial Manager

Senior Medical Director, Translational Medicine & Early Clinical Development

Clinical Trial Specialist

Associate Director, Clinical Operations

Senior Manager, Commercial Procurement

Associate Director, Data Platforms

Financials (FY2025)

Hiring Trend